BiotechTube

Setmelanotide + Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bardet Biedl Syndrome (BBS)

Conditions

Bardet Biedl Syndrome (BBS), Alström Syndrome (AS)

Trial Timeline

Nov 23, 2018 → Mar 8, 2021

NCT ID
NCT03746522

About Setmelanotide + Placebo

Setmelanotide + Placebo is a phase 3 stage product being developed by Rhythm Pharmaceuticals for Bardet Biedl Syndrome (BBS). The current trial status is completed. This product is registered under clinical trial identifier NCT03746522. Target conditions include Bardet Biedl Syndrome (BBS), Alström Syndrome (AS).

What happened to similar drugs?

0 of 2 similar drugs in Bardet Biedl Syndrome (BBS) were approved

Approved (0) Terminated (0) Active (2)
🔄Setmelanotide 2 mg + Setmelanotide 2.5 mg + Setmelanotide 3 mg + Setmelanotide 20 mg + Setmelanotide 25 mg + Setmelanotide 30 mgRhythm PharmaceuticalsPhase 3
🔄SetmelanotideRhythm PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (10)

NCT IDPhaseStatus
NCT06760546Phase 3Recruiting
NCT05774756Phase 3Active
NCT05093634Phase 3Active
NCT04963231Phase 2Completed
NCT03746522Phase 3Completed
NCT03287960Phase 3Completed
NCT02896192Phase 3Completed
NCT02311673Phase 2Completed
NCT02041195Phase 1/2Completed
NCT01749137Phase 2Completed

Competing Products

3 competing products in Bardet Biedl Syndrome (BBS)

See all competitors
ProductCompanyStageHype Score
Setmelanotide 2 mg + Setmelanotide 2.5 mg + Setmelanotide 3 mg + Setmelanotide 20 mg + Setmelanotide 25 mg + Setmelanotide 30 mgRhythm PharmaceuticalsPhase 3
37
SetmelanotideRhythm PharmaceuticalsPhase 3
37
Setmelanotide, administered subcutaneously [SC], once daily.Rhythm PharmaceuticalsPre-clinical
23